Clean, humanized data and data systems are the crucial fuel for engines driving new AI capabilities and uses across the ...

Terran Biosciences' founder and CEO Sam Clark talks about big opportunities for prodrug development in 2025, the importance of a strong medicinal chemistry team, and a potential increase in M&A ...

The life sciences industry contributed nearly $4 billion to the U.S. economy in 2021 and is expected to continue growing an average 7% to 8% per year over the next five years. With an increasing ...

NCBiotech and their coalition of partners received a $25 million Phase 2 award from the U.S. Economic Development Administration’s Build Back Better Regional Challenge. This award will further ...

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing ...

Materials used in a drug package or device design are fundamental to ensuring a safe and effective drug development program. The recent growth in complex therapeutics has increased demand for ...

Oxygen is the second leading cause for quality degradation of pharmaceuticals, water being the first. While we typically think of packaging as the primary resource used to protect drugs from the ...

Life Biosciences' Jerry McLaughlin and Forge Biologics' John Maslowski explain the importance of transparency and collaboration when encountering manufacturing speed bumps.

Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and ...

Eamonn Hobbs brings decades of drug device innovation experience to helm Syncromune's promising Sync-T solid tumor therapeutic platform.

CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and ...